SLC1A5 and Parkinson disease: DB09295 (Talniflumate) is an anti-inflammatory drug that exerts neuroprotective effects by inhibiting astrocytic ASCT2–NLRP3 interaction, thereby reducing neuroinflammation and preserving dopaminergic neurons in Parkinson’s disease models [114].